Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute. [More]
Study shows aggressive end-of-life care for young cancer patients may be less effective

Study shows aggressive end-of-life care for young cancer patients may be less effective

In the last month of their lives, younger cancer patients continued to be hospitalized and receive other aggressive treatment at high rates, a University of North Carolina Lineberger Comprehensive Cancer Center-led study found. [More]
Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting. [More]
IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. [More]
Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found. [More]
Combination therapy equally good at treating small cell lung cancer

Combination therapy equally good at treating small cell lung cancer

HAVING radiotherapy once a day for six and a half weeks or twice a day for three weeks -- when combined with chemotherapy -- is equally good at treating small cell lung cancer that hasn't spread. [More]
Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago. [More]
Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center. [More]
Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. [More]
FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. [More]
Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Generally, it is thought that there is a connection between concentrations of ammonia and liver disease, such as fatty liver and cirrhosis, Helicobacter pylori (H. pylori) infection, and kidney failure. [More]
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
Lancet study links worldwide economic crisis to increased cancer mortality

Lancet study links worldwide economic crisis to increased cancer mortality

Unemployment and reduced public-sector health spending following the 2008 global economic crisis were associated with increased cancer mortality, according to a new study published in The Lancet. [More]
Advanced cancer patients lack palliative, hospice care

Advanced cancer patients lack palliative, hospice care

Medical societies, including the American Society of Clinical Oncology, recommend that patients with advanced cancer receive palliative care soon after diagnosis and receive hospice care for at least the last three days of their life. Yet major gaps persist between these recommendations and real-life practice, a new study shows. [More]
SBP scientists discover new regulator of immune responses

SBP scientists discover new regulator of immune responses

Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors. [More]
Early diagnosis of lung cancer can increase survival rate by 73%

Early diagnosis of lung cancer can increase survival rate by 73%

The UK Lung cancer screening trial (UKLS) has been successfully completed and demonstrated that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance of surviving for five years or more. The UKLS trial was conducted by experts in the University of Liverpool. [More]
Researchers emphasize need to rethink tobacco control strategies

Researchers emphasize need to rethink tobacco control strategies

The tobacco product landscape has changed significantly with the introduction of alternatives that are much less harmful than traditional cigarettes. [More]
New Rutgers research aims at exploring gender differences in lung cancer

New Rutgers research aims at exploring gender differences in lung cancer

Lung cancer is the leading cause of cancer death in both men and women. Lung cancer diagnoses have more than doubled among females in the past 38 years, while having fallen 29 percent among males, according to the American Lung Association. [More]
Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

The lab of Rice University synthetic organic chemist K.C. Nicolaou has reported the streamlined total synthesis of delta12-prostaglandin J3, a molecule previously claimed to kill leukemic cancer cells. [More]
Advertisement